Protagonist Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Protagonist Therapeutics' es Dinesh Patel , nombrado en Dec 2008, tiene una permanencia de 15.33 años. compensación anual total es $5.99M, compuesta por 10.5% salario y 89.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.78% de las acciones de la empresa, por valor de $11.20M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 9.3 años, respectivamente.
Información clave
Dinesh Patel
Chief Executive Officer (CEO)
US$7.1m
Compensación total
| Porcentaje del salario del CEO | 9.3% |
| Permanencia del CEO | 15.4yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 9.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13
Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04How Many Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Did Insiders Buy, In The Last Year?
Feb 09We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn
Dec 18Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$7m | US$655k | -US$79m |
| Sep 30 2023 | n/a | n/a | -US$140m |
| Jun 30 2023 | n/a | n/a | -US$138m |
| Mar 31 2023 | n/a | n/a | -US$140m |
| Dec 31 2022 | US$6m | US$630k | -US$127m |
| Sep 30 2022 | n/a | n/a | -US$130m |
| Jun 30 2022 | n/a | n/a | -US$133m |
| Mar 31 2022 | n/a | n/a | -US$122m |
| Dec 31 2021 | US$6m | US$600k | -US$126m |
| Sep 30 2021 | n/a | n/a | -US$108m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$70m |
| Dec 31 2020 | US$2m | US$565k | -US$66m |
| Sep 30 2020 | n/a | n/a | -US$65m |
| Jun 30 2020 | n/a | n/a | -US$73m |
| Mar 31 2020 | n/a | n/a | -US$83m |
| Dec 31 2019 | US$2m | US$545k | -US$77m |
| Sep 30 2019 | n/a | n/a | -US$74m |
| Jun 30 2019 | n/a | n/a | -US$66m |
| Mar 31 2019 | n/a | n/a | -US$45m |
| Dec 31 2018 | US$4m | US$520k | -US$39m |
| Sep 30 2018 | n/a | n/a | -US$28m |
| Jun 30 2018 | n/a | n/a | -US$24m |
| Mar 31 2018 | n/a | n/a | -US$31m |
| Dec 31 2017 | US$790k | US$475k | -US$37m |
Compensación vs. Mercado: La compensación total ($USD5.99M) de Dinesh está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Dinesh ha aumentado mientras la empresa no es rentable.
CEO
Dinesh Patel (66 yo)
15.4yrs
Permanencia
US$7,067,572
Compensación
Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He served as Interim Chief Financ...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President | 15.4yrs | US$7.07m | 0.77% $ 11.9m | |
| Executive VP & Chief Financial Officer | 2.1yrs | US$1.40m | 0.0038% $ 57.5k | |
| Chief Development Officer | 5.3yrs | US$2.22m | 0.25% $ 3.8m | |
| Founder & VP Technology | 3.3yrs | sin datos | sin datos | |
| Executive VP & Chief Technical Officer | 3.3yrs | sin datos | sin datos | |
| Executive VP & General Counsel | 3.7yrs | sin datos | sin datos | |
| Head of HR & Senior VP of Human Resources | 3.3yrs | sin datos | sin datos | |
| Executive VP & Chief Drug Discovery and Preclinical Development Officer | 3.3yrs | sin datos | sin datos | |
| Executive Vice President of Business Development | 3.1yrs | sin datos | sin datos | |
| Executive Vice President of Portfolio & Program Management | 3.3yrs | sin datos | sin datos | |
| Chief Medical Officer | 1.5yrs | sin datos | 0.0070% $ 106.5k | |
| Interim Head of Regulatory Affairs & Advisor | no data | sin datos | sin datos |
3.3yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PTGX se considera experimentado (3.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President | 15.4yrs | US$7.07m | 0.77% $ 11.9m | |
| Clinical Advisor | 9.3yrs | sin datos | sin datos | |
| Independent Director | 6.9yrs | US$351.52k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 9.3yrs | US$188.07k | sin datos | |
| Independent Chairman | 15.3yrs | US$395.27k | 0.048% $ 730.4k | |
| Independent Director | 7.8yrs | US$364.02k | 0.020% $ 313.0k | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Clinical Advisor | no data | sin datos | sin datos | |
| Clinical Advisor | no data | sin datos | sin datos | |
| Clinical Advisor | no data | sin datos | sin datos | |
| Independent Director | 6yrs | US$356.52k | 0.031% $ 469.6k |
9.3yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de PTGX se considera experimentada (9.3 años de antigüedad promedio).